Hemophiliacs File Suit Against Bayer for selling Tainted Blood product
Tue, 3 Jun 2003
The Los Angeles Times reports that two weeks after The New York Times reported that Bayer documents reveal that the company sold tainted blood-clotting medicine for hemophiliacs that carried a high risk of transmitting AIDS to Asia and Latin America in the mid-1980’s, while selling a new, safer product in the West, a lawsuit has been filed in federal court in California on behalf of thousands of hemophiliacs.
Bayer claims that the company said it acted responsibly “and in line with the best medical knowledge at the time.” However, the LA Times reports, “Bayer and three other companies that made the concentrate settled 15 years of U.S. lawsuits from people who took the drug, paying about $600 million.”
Hemophiliacs are among a continuing trail of human casualties that suffered and died as a result of corrupt practices by Bayer Pharmaceuticals.
LOS ANGELES TIMES
Suit Says Drugs Made From Tainted Blood
By KIM CURTIS, Associated Press Writer
SAN FRANCISCO — Several hemophiliacs filed a lawsuit against Bayer Corp. and other companies, claiming they exposed patients to HIV and hepatitis C by selling medicine made with blood from sick, high-risk donors.
The lawsuit alleges the companies continued distributing the blood-clotting product in Asia and Latin America in 1984 and 1985, even after they stopped selling it in the United States because of the known risk of HIV and hepatitis transmission.
The lawsuit filed Monday in federal court seeks class-action status on behalf of thousands of foreign hemophiliacs who received the product, said attorney Robert Nelson. It accuses the companies of negligence and fraudulent concealment.
“This is a worldwide tragedy,” Nelson said. “Thousands of hemophiliacs have unnecessarily died from AIDS and many thousands more are infected with HIV or hepatitis C.”
Bayer rejected the claims, saying in a statement from its headquarters in Leverkusen, Germany Tuesday that it would examine the lawsuit and prepare its defense.
“Bayer at all times complied with all regulations in force in the relevant countries based on the amount of scientific evidence available at the time,” the company said, adding that decisions made 20 years ago should not be judged by today’s scientific knowledge.
Nelson said the lawsuit was filed in California because defendant Cutter Biological, now a division of Bayer, was formerly based in Berkeley. Several plasma donation sites also were located in the San Francisco Bay area, he said.
The lawsuit was filed less than two weeks after an investigation by The New York Times accused the company of selling old stock of the medicine abroad, while marketing a newer, safer product in the United States. Bayer told Times it sold the old medicine because some customers doubted the effectiveness of a new version of the product, and because some countries were slow to approve its sale.
While the company said it acted responsibly and in line with the best medical knowledge at the time, Bayer and three other companies that made the concentrate settled 15 years of U.S. lawsuits from people who took the drug, paying about $600 million.
The medicine, called Factor VIII concentrate, can stop or prevent potentially fatal bleeding in people with hemophilia.
Early in the AIDS epidemic, the medicine was commonly made using mingled plasma from 10,000 or more donors. Because there was not yet a screening test for HIV, the virus that causes AIDS, thousands of hemophiliacs were infected.
But the lawsuit alleges Bayer and the others refused to take precautions that could have made the product safer.
As of 1992, the contaminated blood products had infected at least 5,000 hemophiliacs in Europe with HIV. More than 2,000 had already developed AIDS and 1,250 had died from the disease, the lawsuit said.
By the mid-1990s in Japan, hemophiliacs accounted for the majority of the country’s 4,000 reported cases of HIV infection and virtually all infections of Japan’s hemophiliacs have been linked to contaminated blood products imported from the United States, the lawsuit said. In Latin America, at least 700 HIV cases are linked to use of contaminated blood products by hemophiliacs, the lawsuit said.
FAIR USE NOTICE: This may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available to advance understanding of ecological, political, human rights, economic, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior general interest in receiving similar information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml If you wish to use copyrighted material for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.